A Phase III Multicenter Open Label Long Term Study of the Safety Tolerablity and Efficacy of Intravenous Antegren (Natalizumab) in Chron's Disease Subjects Who Have Previously Participated in Studies CD251 CD301 CD303 or CD306 (ELN100226-CD351)